Clinical Trials Logo

Malignant Conjunctival Neoplasm clinical trials

View clinical trials related to Malignant Conjunctival Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00482911 Terminated - Clinical trials for Intraocular Melanoma

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Start date: April 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with sunitinib and low doses of cyclophosphamide once a day may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with sunitinib and cyclophosphamide works in treating patients with stage IV eye melanoma.